creatinine raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
Commercial creatine products appear in several forms, including monohydrate, hydrochloride, citrate, nitrate, and ethyl ester. Creatine monohydrate is the most studied form and serves as a reference material in comparative research. Different forms vary in solubility, pH, and water content, but they share creatine as the active moiety after dissolution. Claims that one form is uniformly superior remain debated, and study designs often differ in population, exercise protocol, and outcome measures. Purity and hydration state are central to interpreting product labels.
Creatine monohydrate is the hydrated form of creatine, a nitrogen-containing organic acid involved in cellular energy transfer. Its molecular formula is C4H11N3O3, and it consists of creatine plus one water molecule in the crystal lattice. The anhydrous base, creatine, has the formula C4H9N3O2. The compound appears as a white, odorless, crystalline powder and is classified as a guanidine derivative. It is distinct from creatinine, a breakdown product measured in clinical chemistry.
In animals, creatine is synthesized mainly in liver, kidney, and pancreas from arginine, glycine, and methionine. The first committed step transfers a guanidino group from arginine to glycine, forming guanidinoacetate. Subsequent methylation by S-adenosylmethionine yields creatine. Dietary sources include meat and fish; endogenous synthesis supplies part of the body pool. Most creatine is stored in skeletal muscle, where it is converted to phosphocreatine and participates in rapid regeneration of adenosine triphosphate during short, intense activity.
Creatine monohydrate is sold as a dietary ingredient in some countries and as a food supplement in others. Regulatory frameworks vary, so purity limits, labeling rules, and permitted claims are not globally uniform. In the United States, it falls under dietary supplement rules, whereas the European Union treats it as a food supplement ingredient. Pharmacopeial monographs, where they exist, can provide public quality standards, but not every product is required to meet them. Questions about long-term effects and patterns of use remain areas of active study rather than settled regulatory findings.
Solid creatine monohydrate is generally stable when kept cool and dry, but it can hydrolyze to creatinine over time. Moisture, heat, and acidic conditions accelerate this conversion, which reduces assay values and changes the material's properties. Creatinine is a cyclic dehydration product that is also a normal human metabolite, so its presence in a sample is not necessarily a health concern by itself. In quality testing, creatinine is monitored as a marker of degradation and purity.
| Property | Value | Notes |
|---|---|---|
| Chemical formula (monohydrate) | C4H11N3O3 | Includes one water molecule per creatine unit. |
| Molecular weight | 149.15 g/mol | Calculated for the monohydrate; anhydrous creatine is 131.13 g/mol. |
| Appearance | White crystalline powder | Odorless; particle size can vary by manufacturing. |
| CAS Registry Number | 6020-87-7 | Identifies creatine monohydrate; creatine base is 57-00-1. |
| Common synonyms | Creatine hydrate; methylguanidoacetic acid monohydrate | Naming varies by registry and supplier. |
Creatine is synthesized endogenously in humans, mainly in the liver, kidney, and pancreas, from the amino acids arginine, glycine, and methionine. Skeletal muscle stores much of the body's creatine, where it participates in the phosphocreatine system that buffers adenosine triphosphate during short, intense contractions. Dietary sources include meat and fish, so omnivorous diets provide additional creatine beyond endogenous production. Supplemental creatine monohydrate supplies the same molecule found in food and tissues, not a distinct drug or hormone. Research interest centers on its role in cellular energy transfer and its effects on muscle and other tissues.
Several creatine forms are sold, including monohydrate, anhydrous, hydrochloride, nitrate, citrate, and blends. Once dissolved, these forms deliver creatine, but they differ in molar mass, solubility, counterions, and water content. Creatine monohydrate has the largest body of published human data among these forms. Questions remain about whether any alternative form offers meaningful advantages in absorption, tolerability, or tissue uptake under practical conditions. The hydrate form's lower creatine content by mass is a compositional fact, not a statement about effectiveness.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine associates with one molecule of water in the solid lattice. Its molecular formula is C4H11N3O3, and its molar mass is about 149.15 grams per mole. The material appears as a white, odorless powder that dissolves sparingly in water at room temperature. The monohydrate designation distinguishes it from anhydrous creatine, which lacks the bound water and has a lower molar mass. This hydrate is the most common commercial form of creatine used in nutritional and research settings.
Identity and purity are commonly assessed by high-performance liquid chromatography, often with ultraviolet detection, and by spectroscopic techniques such as infrared or nuclear magnetic resonance. These methods can distinguish creatine from creatinine and detect related impurities. Moisture content may be measured by Karl Fischer titration or loss on drying. Particle size, bulk density, and heavy metal limits are additional quality parameters. Not every product is tested by every method, so specifications depend on the intended use and regulatory framework.
Solid creatine monohydrate is generally stable when kept dry and protected from extremes of heat and humidity. In the presence of moisture, it can gradually convert to creatinine, a cyclic dehydration product that has little value for phosphocreatine synthesis. Elevated temperatures and acidic conditions accelerate this conversion in solution. Because the reaction is slow in cool, dry storage, typical shelf lives are measured in years rather than weeks. Packaging that limits moisture and oxygen exposure helps maintain purity.
Pelage Pharmaceuticals presented on suvomipic at the American Academy of Dermatology (AAD) Annual Meeting 2026 in March 2026, including disclosing some new phase 2a trial data, but did not provide the open-label extension data at this event. Phase 3 trials of suvomipic for alopecia are being planned for 2026. It has been estimated that if suvomipic is successful in clinical trials and passes regulatory scrutiny, the drug could be approved for the treatment of hair loss sometime between 2027 and 2029 at the earliest. Suvomipic is currently Pelage Pharmaceuticals's only official drug candidate. However, the company is also investigating reactivation of dormant stem cells for treatment of other medical conditions. Pelage Pharmaceuticals had raised more than $30 million by August 2025, with investment being led by Google Ventures of Alphabet. In October 2025, it was announced that the company had raised $120 million. In 2019, Pelage Pharmaceuticals had reached an agreement that granted Allergan (now AbbVie) an option to acquire the startup company, but this deal was terminated in 2020. Suvomipic may also have applications in the treatment of other forms of hair loss besides androgenic alopecia. In October 2025, Time magazine named suvomipic one of the best inventions of 2025. However, the magazine also disclosed, via communication with Pelage Pharmaceuticals, that suvomipic may not be effective in the end stages of balding if the hair follicle is "scarred".
=== Channel 4 === In 2007, Willis guest hosted the tenth week of Big Brother's Big Mouth. In 2010, Willis began presenting a Celebrity Big Brother online spin-off show entitled Celebrity Big Brother's Bit on The Side. While presenting the online spin-off in the same series, Willis also presented another edition of Big Mouth when Davina McCall entered the Big Brother house as part of a task. She was then later announced in August as the new co-presenter on the final series of Big Brother's Little Brother, hosting opposite George Lamb. In June 2019, Willis replaced Alice Levine and Maya Jama as host of The Circle.
== Dietary intake == As mentioned before, selenomethionine occurs in the human diet. It is one of the main forms of selenium in food along with selenocystine. Selenomethionine is readily available as a dietary supplement. It has been suggested by nutritionists that selenomethionine, as an organic form of selenium, is easier for the human body to absorb than selenite, which is an inorganic form. It was determined in a clinical trial that selenomethionine is absorbed 19% better than selenite.
== BOLD-100 derivatives == BOLD-100 is sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)] with cesium as an intermediate salt form. BOLD-100 was developed from KP1339 (also known as IT-139 or NKP-1339) which is also sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)], but has different manufacturing methods and purity profiles. The names are often used interchangeably. The precursor to BOLD-100 is KP1019, which is the indazole salt equivalent. KP1019 previously entered Phase 1 clinical trials but development was halted due to low solubility in water, leading to the development of KP1339 and BOLD-100 which are readily soluble in water. KP1019 and KP1339 were invented by Dr. Keppler at the University of Vienna.
=== Environmental impacts === In 2022 the Organisation for Economic Co-operation and Development (OECD) proposed that pharmaceutical companies should be required to collect and destroy unused or expired medicines that they have put on the market in order to reduce public health risks around the misuse of medicines obtained from waste bins, the development of antimicrobial resistant bacteria from the discharge of antibiotics into environmental systems and "economic losses" from wasted healthcare resources. Potentially harmful concentrations of pharmaceutical waste has been detected in more than a quarter of water samples taken from 258 rivers around the world. OECD recommend that medicines should be collected separately from household waste and that "marketplaces and redistribution platforms for unused close-to-expiry-date medicines" should be set up. Such extended producer responsibility schemes are already running in France, Spain and Portugal.
Sources: en.wikipedia.org
=== Aggregation of safety data during clinical development === Aggregating safety data across clinical trials during drug development is important because trials are generally designed to focus on determining how well the drug works. The safety data collected and aggregated across multiple trials as the drug is developed allows the sponsor, investigators and regulatory agencies to monitor the aggregate safety profile of experimental medicines as they are developed. The value of assessing aggregate safety data is: a) decisions based on aggregate safety assessment during development of the medicine can be made throughout the medicine's development and b) it sets up the sponsor and regulators well for assessing the medicine's safety after the drug is approved.
As with all catalysts, enzymes do not alter the position of the chemical equilibrium of the reaction. In the presence of an enzyme, the reaction runs in the same direction as it would without the enzyme, just more quickly. For example, carbonic anhydrase catalyzes its reaction in either direction depending on the concentration of its reactants:
Alongside his collaborators, Karl Piez and George Martin at the National Institute of Health, Gross discovered that collagen was composed of three polypeptide chains. These experiments opened up the field of collagen biology. In the early 1960s, Gross began searching for mechanisms whereby collagen fibers are degraded during tissue remodeling alongside Belgian postdoctoral fellow Charles Lapiere. Gross reasoned that collagenolytic enzymes, which previously had been identified only in bacteria, could be made only when and where they were needed. They looked for collagenase in the medium from tissue implants in culture. Together, they found the enzyme and characterized its mechanism of action and its unique cleavage site. With such colleagues as Martin Tanzer, Utaka Nagai, Andrew Kang, and others, Gross continued studies of mechanisms of collagenolysis, lathyrism, and wound healing. In 1969, Gross was promoted to Professor of Medicine at Harvard Medical School and named Biologist at the Massachusetts General Hospital. Scientists from all over the world worked in Gross's Developmental Biology Laboratory in the Department of Medicine at the Massachusetts General Hospital. Gross continued to make important observations on collagen structure, mechanisms of fibrillogenesis, the role of hyaluronic acid and hyaluronidase in wound healing, embryogenesis and limb regeneration, the origin of corneal ulcers, and control of collagenase production. Gross died at age 96 in Waban, Massachusetts of natural causes
=== Generic names === Mirtazapine is the English and French generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and JANTooltip Japanese Accepted Name. Its generic name in Spanish, Italian, and Portuguese is mirtazapina and in German, Turkish and Swedish is mirtazapin.
Sources: en.wikipedia.org
=== As an indicator of volcanic activity === Sulfur dioxide content in naturally-released geothermal gasses is measured by the Icelandic Meteorological Office as an indicator of possible volcanic activity.
While such infrastructure has always been associated with some risk, the dependency of Denmark and its allies on them are only increasing and is therefore posing a major threat in times of tension short of actual conflict.
Cyclic glycine-proline (cGP) is a small neuroactive peptide that belongs to a group of bioactive 2,5-diketopiperazines (2,5-DKPs) and is also known as cyclo-glycine-proline. cGP is a neutral, stable naturally occurring compound and is endogenous to the human body; found in human plasma, breast milk and cerebrospinal fluid. DKPs are bioactive compounds often found in foods. Cyclic dipeptides such as 2,5 DKPs are formed by the cyclisation of two amino acids of linear peptides produced in heated or fermented foods. The bioactivity of cGP is a property of functional foods and presents in several matrices of foods including blackcurrants. cGP is metabolite of hormone insulin-like growth factor-1 (IGF-1). It has a cyclic structure, lipophilic nature, and is enzymatically stable which makes it a more favorable candidate for manipulating the binding-release process between IGF-1 and its binding protein thereby, normalizing IGF-1 function. Under the trade name Traneurocin (developmental code name NA-831), it is being developed as a racetam-like drug for the treatment of COVID-19, Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder, and other neurological disorders. In the case of COVID-19, it is specifically being developed for treatment of COVID-19-induced neuropathy.
== Structure and reactivity == DBNPA is a halogenated cyanoacetamide compound, characterized by the presence of two bromine atoms at the 2,2-position of the carbon backbone. DBNPA contains a cyano (-CN) group and an amide (-CONH2) group attached to a three-carbon chain. The molecular formula is C3H2Br2N2O, with a molecular weight of 241.87 g/mol. DBNPA is highly reactive due to the two electron-withdrawing bromine atoms and a cyano (-CN) group attached to the central carbon backbone. These substituents form a very electron-deficient core, making it highly vulnerable to nucleophilic attacks. The cyano group increases the reactivity of the compound by stabilizing the electron deficiency while the amide (−CONH2) group affects its water solubility. The electron-deficient carbon adjacent to the bromine atoms plays a critical role in DBNPA’s biocidal properties, leading to the disruption of microbial cellular functions. Since DBNPA is a highly reactive molecule, it is prone to pH-dependent hydrolysis at neutral and alkaline conditions because of the weak carbon-bromide bonds. DBNPA is also susceptible to be broken down in reducing environments by stepwise debromination. Additionally, DBNPA is highly sensitive to ultraviolet (UV) exposure, which accelerates its degradation in aqueous environments. Due to its reactive nature, DBNPA must be stabilized in products to prevent premature degradation before application.
Drug content Release of medicament from base Medicament penetration Consistency of the preparation Absorption of medicament into blood stream Irritant effect Properties which affect choice of an ointment base are:
Sources: en.wikipedia.org
Creatine is the base compound, while creatine monohydrate includes one water molecule per creatine molecule in its crystal structure. The monohydrate form is common in supplements and analytical standards. The body uses creatine itself after the water is removed or dissociated.
Yes. Meat, fish, and other animal tissues contain creatine. Cooking can convert some creatine to creatinine, which has no role in phosphocreatine energy buffering. Plant foods contain little or no creatine.
Creatinine is a cyclic breakdown product formed from creatine and phosphocreatine. It is filtered by the kidneys and commonly measured in blood and urine as a marker of renal function. Creatine monohydrate is a supplement ingredient and research chemical, not the same molecule.
A sealed container kept at room temperature and away from moisture is typical. Heat and humidity promote conversion to creatinine and can reduce assay values. Long-term storage under dry conditions helps maintain the original crystalline form.